Your browser doesn't support javascript.
loading
Cisplatin and 5-fluorouracil with or without epidermal growth factor receptor inhibition panitumumab for patients with non-resectable, advanced or metastatic oesophageal squamous cell cancer: a prospective, open-label, randomised phase III AIO/EORTC trial (POWER).
Moehler, M; Maderer, A; Thuss-Patience, P C; Brenner, B; Meiler, J; Ettrich, T J; Hofheinz, R-D; Al-Batran, S E; Vogel, A; Mueller, L; Lutz, M P; Lordick, F; Alsina, M; Borchert, K; Greil, R; Eisterer, W; Schad, A; Slotta-Huspenina, J; Van Cutsem, E; Lorenzen, S.
Affiliation
  • Moehler M; 1st Department of Internal Medicine, Johannes Gutenberg-University Mainz, Mainz, Germany. Electronic address: markus.moehler@unimedizin-mainz.de.
  • Maderer A; 1st Department of Internal Medicine, Johannes Gutenberg-University Mainz, Mainz, Germany.
  • Thuss-Patience PC; Medical Department, Division of Hematology, Oncology and Tumor Immunology, Charité - University Medicine Berlin, Berlin, Germany.
  • Brenner B; Institute of Oncology, Davidoff Center, Rabin Medical Center, Petach Tikva and Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
  • Meiler J; Department of Internal Medicine, University Hospital Essen, Essen, Germany.
  • Ettrich TJ; Department of Internal Medicine I, University Hospital Ulm, Ulm, Germany.
  • Hofheinz RD; Medical Department III, University Hospital Mannheim, Mannheim, Germany.
  • Al-Batran SE; Institute of Clinical Cancer Research, Hospital North-West, Frankfurt, Germany.
  • Vogel A; Department of Gastroenterology, Hepatology and Endocrinology, Hannover Medical School, Hannover, Germany.
  • Mueller L; Oncology Leer-Emden-Papenburg, Leer, Germany.
  • Lutz MP; Gastroenterology, Caritas Hospital, Saarbrücken, Germany.
  • Lordick F; 1st Medical Department and University Cancer Center Leipzig, University of Leipzig Medical Center, Leipzig, Germany.
  • Alsina M; Department of Medical Oncology, Hospital Universitari Vall d'Hebron and Vall d'Hebron Institute of Oncology, Universitat Autònoma de Barcelona, Barcelona, Spain.
  • Borchert K; Medical Department III, University Hospital Rostock, Rostock, Germany.
  • Greil R; 3rd Medical Department, Cancer Research Institute, Paracelsus Medical University Salzburg, Salzburg, Austria.
  • Eisterer W; Department of Internal Medicine V, Medical University Innsbruck, Innsbruck, Austria.
  • Schad A; Institute of Pathology, Johannes Gutenberg-University Mainz, Mainz, Germany.
  • Slotta-Huspenina J; Institute of Pathology, School of Medicine, Technical University of Munich, Munich, Germany.
  • Van Cutsem E; University Hospitals Gasthuisberg Leuven and KU Leuven, Leuven, Belgium.
  • Lorenzen S; Medical Department III, Klinikum rechts der Isar, Technical University of Munich, Munich, Germany.
Ann Oncol ; 31(2): 228-235, 2020 02.
Article in En | MEDLINE | ID: mdl-31959339
Subject(s)
Key words
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Health context: 6_ODS3_enfermedades_notrasmisibles Database: MEDLINE Main subject: Esophageal Neoplasms / Carcinoma, Squamous Cell / Antineoplastic Combined Chemotherapy Protocols Type of study: Clinical_trials / Observational_studies Limits: Humans Language: En Journal: Ann Oncol Year: 2020 Document type: Article
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Health context: 6_ODS3_enfermedades_notrasmisibles Database: MEDLINE Main subject: Esophageal Neoplasms / Carcinoma, Squamous Cell / Antineoplastic Combined Chemotherapy Protocols Type of study: Clinical_trials / Observational_studies Limits: Humans Language: En Journal: Ann Oncol Year: 2020 Document type: Article